Prostate Cancer - Results from #24880

PSA progression under hormone therapy - of prognostic relevance? - Abstract September 5, 2012

The factors for continuing docetaxel-based chemotherapy for castration-resistant prostate cancer - Abstract September 5, 2012

Patient specific prostate segmentation in 3D magnetic resonance images - Abstract September 5, 2012

Osteoporosis in men receiving androgen deprivation therapy for non-metastatic prostate cancer - Abstract September 5, 2012

Effects of radiation and total androgen blockade on serum hemoglobin, testosterone, and erythropoietin in patients with localized prostate cancer - Abstract September 5, 2012

Cabazitaxel after docetaxel: A new option in metastatic castration-resistant prostate cancer - Abstract September 5, 2012

Blood flow and oxygenation status of prostate cancers - Abstract September 5, 2012

Associations of serum sex steroid hormones and 5α-androstane-3α,17β-diol glucuronide concentrations with prostate cancer risk among men treated with finasteride - Abstract September 5, 2012

Statin use and risk of prostate cancer in the prospective Osteoporotic Fractures in Men (MrOS) Study - Abstract September 5, 2012

Simultaneous robot-assisted laparoscopic cystectomy and laparoscopic nephrectomy: First experience on 3 patients with short-term follow-up - Abstract September 4, 2012

Hypofractionated radiation therapy for prostate cancer: Risks and potential benefits in a fiscally conservative health care system - Abstract September 4, 2012

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A cost-effectiveness analysis - Abstract September 4, 2012

Preventing bone complications in prostate cancer - Abstract September 4, 2012

Genetic link to prostate cancer risk in African Americans found September 4, 2012

Role of prostate-specific antigen change ratio at initial biopsy as a novel decision-making marker for repeat prostate biopsy - Abstract September 4, 2012

PSMA-targeted theranostic nanoplex for prostate cancer therapy - Abstract September 4, 2012

Willingness to pay for prostate cancer treatment among patients and their family members at 1 year after diagnosis - Abstract September 4, 2012

Intermittent LHRH therapy in the management of castrate-resistant prostate cancer (CRPCa): Results of a multi-institutional randomized prospective clinical trial - Abstract September 4, 2012

Is PCA3 score useful in preoperative staging of a single microfocus of prostate cancer diagnosed at saturation biopsy? - Abstract September 4, 2012

Long-term disease stabilization in a patient with castration-resistant metastatic prostate cancer by the addition of lenalidomide to low-dose dexamethasone and celecoxib - Abstract September 4, 2012

Page 1245 of 1436